

## EMPAGLIFLOZIN tablets (Jardiance®) for treating chronic heart failure with preserved or mildly reduced ejection fraction

**The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of EMPAGLIFLOZIN tablets (Jardiance®) for treating chronic heart failure with preserved or mildly reduced ejection fraction.**

### GREY

Empagliflozin has been granted a license extension and is now indicated in adults for the treatment of symptomatic chronic heart failure.<sup>[1]</sup> Previously it was licensed only for heart failure with reduced ejection fraction and the license indication now extends to symptomatic chronic heart failure irrespective of ejection fraction.

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of chronic heart failure should continue to follow national guidance, local pathways and local formulary choices:

- > NICE Guideline [NG106]: [Chronic heart failure in adults: diagnosis and management](#) (12 September 2018)
- > Cheshire and Merseyside Health and Care Partnership: [Heart Failure Pathway](#) (04 November 2021)
- > Pan Mersey APC formulary: [Chapter 2: Cardiovascular system](#)

### References

Boehringer Ingelheim Limited. Summary of Product Characteristics; [Jardiance 10 mg film-coated tablets](#), June 2022. Accessed online 22 September 2022.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.